Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.

ABSTRACT:

Context

Fatigue has been identified in more than one-half of patients with sarcoidosis. Although fatigue is not synonymous with impaired quality of life, most studies of sarcoidosis identify fatigue as a major cause of impaired quality of life.

Objectives

To test the hypothesis that stimulants may have a role in the treatment of fatigued sarcoidosis patients, even without objective evidence of daytime sleepiness.

Methods

This was a double-blind, placebo-controlled, crossover study of sarcoidosis patients followed up in one sarcoidosis clinic Sarcoidosis patients with fatigue received either armodafinil or placebo with eight weeks of therapy for each arm and a two week washout period before crossover to the other treatment. Initial armodafinil dose was 150mg and increa

SUBMITTER: Lower EE 

PROVIDER: S-EPMC3678278 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature